When insulin therapy is introduced in advanced stages of type 2 diabetes mellitus many patients are already being treated with metformin and continue to receive this oral antihyperglycaemic agent. In a systematic review and meta-analysis, Hemmingsen et al. have evaluated the evidence for the benefits of this combination therapy.
This is a preview of subscription content, access via your institution
Access options
References
Inzucchi, S. E. et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55, 1577–1596 (2012).
Hemmingsen, B. et al. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ http://dx.doi.org/10.1136/bmj.e1771.
Bailey, C. J. et al. in Metformin, the Gold Standard. A scientific handbook. (ed. Bailey, C. J. et al.) 1–288 (Wiley, Chichester, 2007)
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854–865 (1998).
Johnson, J. A., Simpson, S. H., Toth, E. L. & Majumdar S. R. Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabetic Med. 22, 497–502 (2005).
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R. & Neil, H. A. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 359, 1577–1589 (2008).
Skyler, J. S. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials. A position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32, 187–192 (2009).
Kooy, A. et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch. Intern. Med. 169, 616–625 (2009).
Zhang, B. B., Zhou, G. & Li, C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab. 9, 407–416 (2009).
Bailey, C. J. Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc. Drugs Ther. 22, 215–224 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares associations with the following companies: Astra Zeneca, Bristol-Myers Squibb, Lilly, MSD and Novo Nordisk (consultancy/speakers bureau); and Boehringer Ingelheim, GlaxoSmithKline, Sanofi and Takeda (consultancy).
Rights and permissions
About this article
Cite this article
Bailey, C. Insulin plus metformin for T2DM—are there benefits?. Nat Rev Endocrinol 8, 449–450 (2012). https://doi.org/10.1038/nrendo.2012.106
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrendo.2012.106